Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dow Jones Industrial Average ETF (DIA) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Dow Jones Industrial Average ETFTrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Dow Jones Industrial Average ETF vs Recursion Pharmaceuticals Inc — how do they compare? Dow Jones Industrial Average ETF trades at $537.34, while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B). The key difference: Dow Jones Industrial Average ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

DIARXRX
52-Week High
$542.79$6.79
52-Week Low
$444.64$2.84
Market Cap
$1.78B
Sector
Health
Enterprise Value
$1.30B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dow Jones Industrial Average ETF

DIA trades at $539.70, up 0.28% today, with a bullish technical signal from moving averages and key support at $538. Recent dividends include $1.41 paid in July 2026, reflecting income stability. The stock benefits from broad market momentum, as highlighted by ETF inflows into U.S. equities (ETF Trends, August 7, 2026).

Outlook remains positive due to technical strength and defensive positioning in blue-chip ETFs, but overbought RSI levels near 86 suggest short-term caution. Risks include market volatility from Fed policy and geopolitical tensions, though institutional support provides a cushion for long-term holders.

Recursion Pharmaceuticals Inc

RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.

Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Dow Jones Industrial Average ETF

The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on DIA

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX